The stock will trade on pipeline catalysts rather than current financials. Monitor SONATA-HCM topline data in Q1 2027 and ZYNQUISTA NDA resubmission in Q4 2026 as the primary value drivers. The $190.6M cash position provides runway through these events, reducing near-term financing risk.
Price Chart
Executive Summary
Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27.6M Novo Nordisk licensing milestone, and a net loss of $31.8M ($0.07/share) vs net income of $3.3M a year ago. The key catalysts are the completion of SONATA-HCM enrollment (topline Q1 2027) and ZYNQUISTA NDA resubmission expected Q4 2026, with $190.6M cash providing runway through these events.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $0.7M vs $28.9M in Q2 2025 (included $27.6M licensing milestone from Novo Nordisk)
- Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025
- SONATA-HCM Phase 3 enrollment completed on time, substantially exceeding 500-patient target; topline results expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated Q4 2026
- Cash and investments $190.6M as of June 30, 2026, up from $125.2M at year-end 2025
- Entered $100M loan facility with Hercules Capital in May 2026; initial $55M tranche funded
Financial Impact
Revenue decline of $28.2M YoY driven by absence of one-time licensing milestone; net loss widened by $35.0M YoY
Risk Factors
- SONATA-HCM Phase 3 failure or mixed results would be a major setback
- ZYNQUISTA NDA resubmission could face delays or additional FDA requirements
- Cash burn rate of ~$16M/quarter may require additional financing before catalysts mature
- INPEFA commercial revenue remains minimal ($0.7M/quarter) with unclear path to profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Aug 6, 2026 8w ago | Press Release | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.92 $2.22 | ▼ −15.63% | ▼ −13.85% | $1.82 (+5.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.89 $2.25 | ▲ +19.05% | ▲ +17.16% | $1.82 (−3.70%) |
May 6, 2026 21w ago | 8-K | $1.68 $1.85 | ▲ +10.12% | ▲ +6.98% | $1.82 (+8.33%) |
Apr 30, 2026 22w ago | 8-K | $1.63 $2.07 | ▼ −26.99% | ▼ −21.71% | $1.82 (−11.66%) |
Apr 30, 2026 22w ago | Press Release | $1.61 $2.21 | ▲ +37.27% | ▲ +32.30% | $1.82 (+13.04%) |
Mar 24, 2026 27w ago | Press Release | $1.72 $1.82 | ▲ +5.81% | ▼ −3.09% | $1.82 (+5.81%) |
Mar 23, 2026 27w ago | Press Release | $1.64 $1.83 | ▲ +11.59% | ▲ +4.17% | $1.82 (+10.98%) |
Mar 16, 2026 28w ago | DEFA14A | $1.62 $1.86 | ▲ +14.81% | ▲ +10.51% | $1.82 (+12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access